BioVie Highlights Potential Long COVID Treatment in Latest Broadcast
New York, Saturday, 19 September 2026.
BioVie presented Phase 2 trial results for its Long COVID drug bezisterim. While primary endpoints lacked overall statistical significance, high-symptom subgroup improvements offer potential for future trials.
National Broadcast Highlights Biotech Pipelines
On Saturday, 19 September 2026, biotechnology firms are utilizing national broadcast media to showcase clinical developments targeting significant healthcare challenges [1]. BioVie (Nasdaq: BIVI) is among the companies featured in the “New to The Street” television program scheduled to broadcast at 6:30 PM Eastern Time [1]. The broadcast reaches audiences in the United States, Latin America, and the Middle East/North Africa markets via Bloomberg Television [1]. Alongside BioVie, companies such as Acurx Pharmaceuticals and Lantern Pharma are presenting their latest strategic commercialization efforts [1]. This media presence underscores the growing investor interest in early-to-mid-stage biotech firms addressing high-impact medical needs [1].
ADDRESS-LC Trial Data and Subgroup Analysis
BioVie CEO Cuong Do presented recent clinical trials evaluating bezisterim as a therapeutic candidate for Long COVID and neurological symptoms [1]. The Phase 2 ADDRESS-LC trial assessed the drug’s potential impact on cognitive impairment, brain fog, and fatigue in people with Long Covid [2]. The study randomized 203 patients to receive twice-daily oral bezisterim or placebo [6]. While the primary analysis showed no statistically significant effect in the overall intent-to-treat population across 22 endpoints, numerical trends favored the drug in 21 endpoints [6]. This proportion represents 95.455 percent of the measured outcomes showing favorable trends despite the lack of overall statistical significance [6]. BioVie categorized subgroup findings in patients with high symptom burden as exploratory and hypothesis-generating, requiring future prospective confirmation [6].
Market Reaction and Future Implications
Following the announcement of the Phase 2 results, the company’s stock dropped by approximately 20 percent, suggesting investors were not fully convinced by the subgroup analysis [3]. Bezisterim is a synthetic derivative of androstenetriol believed to reduce insulin resistance and dampen inflammatory pathways including NFκB and TNFα [3][5]. The mechanism hypothesizes that persistent circulating spike-protein fragments may drive NFκB-mediated inflammation, though this remains a hypothesis rather than proven fact [5]. Other firms like Lantern Pharma are utilizing artificial intelligence platforms to accelerate biomarker-driven oncology drug development, reflecting a broader industry trend toward data-driven discovery [1]. The broadcast aims to communicate these developments directly to investors and industry leaders through an international television distribution network [1].